SERVICE

Biosolvix Technique

bt_bb_section_bottom_section_coverage_image

TechniqueBiosolvix Technique

Biosolvix는 뇌오가노이드를 제작할 수 있는 배양 기술 및 분화기술 보유 (특허: 10-2023-0071807(KR) )
뇌오가노이드를 제작하여 다양한 신경 세포의 마커 발현을 확인할 수 있음

* A: Otx2[R], B:Sox2[G] C: Tuj1[R], D: O4[R],Map2[G], E: Nestin[R], F:Map2[G], G:Tuj1[R] H:NF[G] I: TH[G] J:Tuj1[R], DAPI[B]

Otx2[R]

Otx2[R]

A

Sox2[G]

Sox2[G]

B

Tuj1[R]

Tuj1[R]

C

O4[R],Map2[G]

O4[R],Map2[G]

D

Nestin[R]

Nestin[R]

E

Map2[G]

Map2[G]

F

Tuj1[R]

Tuj1[R]

G

NF[G]

NF[G]

H

TH[G]

TH[G]

I

Tuj1[R]

Tuj1[R]

J

BioSolvix Strength

Biosolvix aims to provide safe and ethically sound services for the development of new drugs, focusing on efficacy and toxicity measurements in humans while minimizing harm to animals.

Item Introduction

Biosolvix offers organoids as a solution to enhance the quality of life for both humans and animals..

Organoids are miniature organs created in the laboratory using the differentiation and 3D cultivation of stem cells.

In 2023, the United States FDA abolished the mandatory requirement for animal testing, and organoids gained prominence as an ethical alternative to address the ethical concerns associated with animal experimentation.

This shift away from mandatory animal testing is expected not only in the United States but also globally..

Our company aims to build an organoid panel by transferring organoid technology, establishing methods for producing various tissue-specific organoids and cancer cell organoids. We also strive to develop personalized drug screening, efficacy assessment, and alternative animal testing methods for toxicity evaluation.

Differentiation

Most domestic and international competitors in the organoid field are primarily university-based and tend to be professor-led startups.

Biosolvix, on the other hand, is primarily led by bio-specialized management and distinguishes itself from existing companies by securing standardized organoid technology, enabling a faster path to commercialization..

We also aim to rapidly establish a presence in the organoid market by securing high-quality organoid technology and technology for developing the most similar organs through collaborations with various companies and universities.

Target market

The current organoid market is experiencing rapid growth, with a compound annual growth rate (CAGR) of 22.1%.

현재 국내 비임상 CRO 시장은 약 6000억원입니다. 당사는 비임상 CRO 시장인 효능 독성 시험 시의 1%의 시장 점유율을(약 60억원) 3년내에 달성하고자 합니다.

Furthermore, as the pharmaceutical and biotech industries continue to grow, we believe that if we expand our presence to include efficacy assessment, drug screening, and drug efficacy testing for various venture companies, our revenue growth will increase significantly.

오가노이드 패널이 구축될 경우, 당사는 BIO USA, BIO KOREA 등을 통하여 홍보를 진행함으로써 오가노이드 CRO 구축에 앞장서고자 합니다.

자금조달 계획

당사는 현재 2023년 seed money로 투자자들에게 10억원을 투자 받고자 합니다.

먼저 약 1억원의 TIPS 투자기관에서 투자를 먼저 받은 후, TIPS를 통하여 약 2년동안 10억원을 확보하고자 합니다.

또한, 2024년에는 100억원의 시리즈 A를 조달함으로써, 기술이전하였던 기술들을 바이오솔빅스 자체적으로 오가노이드 기술을 업그레이 및 패널 뱅킹 구성하고자 합니다.

이러한 자금은 기술이전비용, 연구소 구축, 인력채용, 공동연구개발비용등으로 사용하고자 합니다.

Our Service

바이오솔빅스는 사람에게 안전하고 동물윤리에 최대한 위배되지 않은 신약개발 효력/독성 측정 기술 서비스를 진행 합니다.

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_1.png

Organoid banking

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_2.png

Cancer Organoid

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_3.png

Drug Screening & Drug toxicity study

http://www.biosolvix.com/wp-content/uploads/2023/07/s_bg_4.png

Regenerative Treatment

Your Full Service Lab for Clinical Trials

More About BioSolvix

Opening hours

Mon

9am - 6pm

Tue

9am - 6pm

Wed

9am - 6pm

Thu

9am - 6pm

Fri

9am - 6pm

Sat - Sun

Closed

WRITE USQuotation Request